PTO/SB/08a (08-03)
Approved for use through 97/31/2006, ONB 0851-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number.

Application Number		10531901		
Filing Date		2005-04-18		
First Named Inventor	Martin	OUWERKERK, ET AL		
Art Unit		1746		
Examiner Name				
Attornou Docket Number		NI 021079		

					U.S.	PATENTS			Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹				Name of Patentee or Applicant of cited Document		Columns,Lines whe ant Passages or Rele s Appear	
	1	6106801		2000-08	1-22	BOGDANOVIO	CETAL			
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	lease click the	Add button.	_	Add	
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Patentee or Applicant Reli		Releva	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1									
If you wisl	h to a	dd additional U.S. Publi	shed Ap	plication	citatio	n information p	lease click the Ad	d button	. Add	
				FOREIG	SN PA1	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Kind Code ² i Kind Date Name of Patenter Applicant of cited Document		e or	Pages,Columns,Line where Relevant Passages or Releval Figures Appear	TE			
	1	WO0138591			A2	2001-05-31	ENERGY CON. DE	V. INC		
	2	WO9920422			A1	1999-04-29	HYDRO-QUEBEC			
	3	JP56114801			A	1981-09-09	SUDA SELJIRO			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10531901		
iling Date		2005-04-18		
irst Named Inventor Martin		OUWERKERK, ET AL		
Art Unit		1746		
xaminer Name				
Morney Docket Number		NI 021078		

If you wish	h to a	dd add	ditional For	eign Pate	ent Docu	ument	citation	n infor	nation ple	ease click the	Add buttor	Add			
					NON-F	PATE	NT LITE	ERAT	JRE DOC	UMENTS		Remov	e		
Examiner Initials*	Cite No	(bool		e, journa	I, serial,	symp	osium,	catalo		he article (whate, pages(s)					Тs
	1		CHULZ, ET. 7, 1999, pag			pment	ts in the	Applica	tions of N	anocrystalline	Materials to	Hydrogen	Techn	iologies,	
If you wisl	h to a	dd add	ditional nor	-patent li	iterature	docu	ment cit	itation	informatio	on please clic	k the Add I	outton /	Add		
						EX	CAMINE	R SIG	NATURE						
Examiner	Signa	ture								Date Co	nsidered				
										rmance with				ough a	

1 See Kind Codes of USPTO Patent Documents at wear USPTO_GOLY or MEPP 901.64. If Enter office that issued the document, by the low-letter of (WIPPO Standard ST3), 3 "For dispansee patent outcoment, the robusto of the year of the region or precise the serial runbine of the opatent document, and office of the precise the serial runbine of the opatent document, 4 Kind of document by the appropriate symbols as indicated on the document under WIPPO Standard ST1.68 if possible. Tappic land is to place a check mark here if English language the resistance is attached.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10531901		
	Filing Date		2005-04-18 OUWERKERK, ET AL		
First Named Inventor Martin		Martin			
	Art Unit		1746		
Examiner Name Attorney Docket Number					
		er.	NI 021078		

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CPR 1.97(e/t1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Daniel J. Protrowski/	Date (YYYY-MM-DD)	2007-01-09
Name/Print	Daniel J. Piotrowski	Registration Number	42079

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1450, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1450, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.